IL-21 is a
cytokine with pleiotropic actions, promoting terminal differentiation of B cells, increased Ig production, and the development of Th17 and T follicular helper cells.
IL-21 is also implicated in the development of
autoimmune disease and has antitumor activity. In this study, we investigated the role of
IL-21 in host defense to pneumonia virus of mice (PVM), which initiates an
infection in mice resembling that of respiratory syncytial virus disease in humans. We found that PVM-infected mice expressed
IL-21 in lung CD4(+) T cells. Following
infection,
Il21r(-/-) mice exhibited less lung infiltration by neutrophils than did wild-type (WT) mice and correspondingly had lower levels of the
chemokine CXCL1 in bronchoalveolar lavage fluid and lung parenchyma. CD8(+), CD4(+), and γδ T cell numbers were also lower in the lungs of PVM-infected
Il21r(-/-) mice than in infected WT mice, with normal Th17
cytokines but diminished
IL-6 production in PVM-infected
Il21r(-/-) mice. Strikingly,
Il21r(-/-) mice had enhanced survival following PVM
infection, and moreover, treatment of WT mice with soluble IL-21R-Fc fusion
protein enhanced their survival. These data reveal that
IL-21 promotes the pathogenic inflammatory effect of PVM and indicate that manipulating
IL-21 signaling may represent an immunomodulatory strategy for controlling PVM and potentially other respiratory
virus infections.